| Literature DB >> 35598634 |
Laveil M Allen1, Joanna Shechtel2, Katherine Frederick-Dyer3, L Taylor Davis4, LeAnn S Stokes5, Brent Savoie6, Sumit Pruthi7, Cameron Henry8, Sarah Allen9, Sheryl Redlin Frazier10, Reed A Omary11.
Abstract
Entities:
Mesh:
Substances:
Year: 2022 PMID: 35598634 PMCID: PMC9117225 DOI: 10.1016/j.jacr.2022.05.005
Source DB: PubMed Journal: J Am Coll Radiol ISSN: 1546-1440 Impact factor: 6.240
Contrast shortage mitigation strategies by service
| Service | Strategies |
|---|---|
| Pharmacy and infectious disease | Divide IV iodinated contrast doses from a single bottle using sterile technique |
| Diagnostic radiology | Decrease IV iodinated contrast dose by examination type and patient body habitus |
| Perform multiple examinations from a single contrast bolus (ie, level I trauma assessment starting with CTA neck, followed by CT chest, abdomen and pelvis, and delated CT abdomen and pelvis assessment of the urinary tract) | |
| Reinterpret outside imaging studies to avoid repeating examinations | |
| Protocol all examinations regarding need for contrast | |
| Use ionic ICM as available for nonintravascular procedures | |
| Interventional radiology | Use alternative contrast agents, such as gadolinium, air, and CO2; use ionic ICM for nonintravascular procedures |
| Dilute iodinated contrast as much as possible (ALARA-like protocol) | |
| Radiology technologists | Determine if similar contrast-enhanced CT examinations were recently performed |
| Outpatient clinicians | Consult with radiologists and ACR Appropriateness Criteria regarding iodinated contrast–free alternative examination options, such as ultrasound, MRI, and PET/CT |
| Review upcoming orders and consider rescheduling, changing examination modality, performing without contrast, or scheduling at a different facility | |
| Emergency medicine | Increase use of ultrasound and noncontrast CT for assessment of upper abdominal pain, superficial abscess, and others |
| Require stroke resident approval for CTA/CT perfusion | |
| Restrict code stroke designation for patients within tPA window or suspected large-vessel occlusion | |
| Trauma surgery | Order noncontrast trauma CT chest, abdomen, and pelvis for lower yield indications such as ground-level fall mechanism, isolated head trauma, and isolated extremity orthopedic trauma |
| Urology | Prioritize contrast imaging to new renal mass evaluation with no priors |
| Recommend ultrasound or noncontrast CT for initial hematuria workup | |
| Consider noncontrast CT imaging for cancer staging | |
| Oncology | Delay any contrast-enhanced follow-up imaging scheduled >9 mo from the previous imaging until anticipated end of shortage |
| Recommend ordering any CT chest imaging without contrast unless there is concern for pulmonary embolism | |
| Interventional cardiology | No left ventriculography on “healthy hearts” |
| Limit angiography of the left and right coronary systems to two runs each | |
| Request pharmacy assistance to dilute contrast 50:50 | |
| Use gadolinium contrast for balloon inflation device use |
Note: ALARA = as low as reasonably achievable; CTA = CT angiography; ICM = iodinated contrast media; IV = intravenous; tPA = tissue plasminogen activator.
Tiering System
| CER Level | Tier Designation | Description | Examples |
|---|---|---|---|
| Critical (<7 d of contrast on hand) | Tier 1 | Emergent | Stroke Level I trauma Acute MI Aortic dissection AAA rupture Massive transfusion requirement Inpatients with hemodynamic instability Septic shock with unclear source Pulmonary embolism |
| High risk (7-20 d of contrast on hand) | Tier 2 | Urgent | New cancer workup in stable patients (especially aggressive cancer types such as large renal cell, pancreatic, melanoma, etc) Transplantation workup Infection in a stable patient Postprocedural complication in a stable patient Preoperative workup for a patient scheduled for surgery in >24 h |
| Moderate risk (21-30 d of contrast on hand) | Tier 3 | Routine subacute | Patients with cancer in clinical trials or needing study to determine next step in management Chronic infection requiring regular follow-up |
| Low risk (>30 d of contrast on hand) | Tier 4 | Routine delayed subacute | Cancer follow-up in patient responding to treatment on previous examination without new or concerning symptoms Unexplained microscopic hematuria |
| Tier 5 | Chronic | Annual cancer or lesion follow-up in patients in remission or uneventful clinical status Annual follow-up of syndromic condition with no new clinical concerns Adrenal nodule workup in asymptomatic patient without high-risk features Characterization or follow-up of a renal mass <2 cm |
Note: AAA = abdominal aortic aneurysm; CER = contrast exhaustion risk; MI = myocardial infarction.
Fig. 1Weekly contrast use before and after the implementation of coronavirus disease 2019–induced shortage mitigation efforts. Light blue color denotes weekly contrast use before mitigation efforts (April 1, 2022, to April 28, 2022). Dark blue color denotes weekly contrast use after contrast mitigation efforts (April 29, 2022, to May 6, 2022). The percentage decrease in weekly contrast use is listed above postmitigation totals. VUAH = Vanderbilt University Adult Hospital.